Published April 9, 2025 – We’re excited to share that Abselion is featured in the Spring 2025 issue of Innovations in Pharmaceutical Technology (IPT), highlighting the role of our Amperia system in advancing at-line protein quantification for biologics and viral vector development.
The article — “At-Line Protein Quantification: The Quest for Real-Time Data in Biologic and Viral Vector Development” — explores the growing demand for accessible and responsive analytical tools to support evolving bioprocessing needs.
Amperia, powered by Abselion’s proprietary RED (Redox Electrochemical Detection) technology, enables fast and reliable protein quantification directly from complex samples. By providing timely data at the point of need, Amperia supports more efficient decision-making across upstream and downstream workflows.
With a compact footprint, streamlined operation, and expanding assay compatibility, Amperia is designed to integrate seamlessly into a variety of bioprocess environments — supporting applications across monoclonal antibody and viral vector development.
We’re proud to contribute to the shift toward more flexible and practical analytics in biomanufacturing — and honored to be featured by IPT.
Read the full article on IPT Online here.